These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Molecular Diagnostics and [ de Koster EJ; Morreau H; Bleumink GS; van Engen-van Grunsven ACH; de Geus-Oei LF; Links TP; Wakelkamp IMMJ; Oyen WJG; Vriens D Thyroid; 2024 Jan; 34(1):41-53. PubMed ID: 38009209 [No Abstract] [Full Text] [Related]
3. Quantitative classification and radiomics of [ de Koster EJ; Noortman WA; Mostert JM; Booij J; Brouwer CB; de Keizer B; de Klerk JMH; Oyen WJG; van Velden FHP; de Geus-Oei LF; Vriens D; Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2174-2188. PubMed ID: 35138444 [TBL] [Abstract][Full Text] [Related]
4. Hypoxia-induced modulation of glucose transporter expression impacts Xia H; Chen J; Gao H; Kong SN; Deivasigamani A; Shi M; Xie T; Hui KM Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):787-797. PubMed ID: 31832727 [TBL] [Abstract][Full Text] [Related]
5. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours. Toba H; Kondo K; Sadohara Y; Otsuka H; Morimoto M; Kajiura K; Nakagawa Y; Yoshida M; Kawakami Y; Takizawa H; Kenzaki K; Sakiyama S; Bando Y; Tangoku A Eur J Cardiothorac Surg; 2013 Aug; 44(2):e105-12. PubMed ID: 23674658 [TBL] [Abstract][Full Text] [Related]
6. [ de Koster EJ; de Geus-Oei LF; Brouwers AH; van Dam EWCM; Dijkhorst-Oei LT; van Engen-van Grunsven ACH; van den Hout WB; Klooker TK; Netea-Maier RT; Snel M; Oyen WJG; Vriens D; Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1970-1984. PubMed ID: 34981165 [TBL] [Abstract][Full Text] [Related]
7. Role of 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules. Sebastianes FM; Cerci JJ; Zanoni PH; Soares J; Chibana LK; Tomimori EK; de Camargo RY; Izaki M; Giorgi MC; Eluf-Neto J; Meneghetti JC; Pereira MA J Clin Endocrinol Metab; 2007 Nov; 92(11):4485-8. PubMed ID: 17684046 [TBL] [Abstract][Full Text] [Related]
8. Association of Yoshikawa T; Endo K; Moriyama-Kita M; Ueno T; Nakanishi Y; Dochi H; Uno D; Kondo S; Yoshizaki T Auris Nasus Larynx; 2024 Aug; 51(4):696-702. PubMed ID: 38733874 [TBL] [Abstract][Full Text] [Related]
9. Relationship between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in incidentally detected thyroid cancer. Kim BH; Kim IJ; Kim SS; Kim SJ; Lee CH; Kim YK Cancer Biother Radiopharm; 2010 Jun; 25(3):309-15. PubMed ID: 20578836 [TBL] [Abstract][Full Text] [Related]
10. SUVmax of 18F-FDG PET/CT in the differential diagnosis of benign and malignant thyroid nodules according to tumor volume. Kim TH; Ji YB; Song CM; Kim JY; Choi YY; Park JS; Tae K World J Surg Oncol; 2015 Jul; 13():217. PubMed ID: 26179774 [TBL] [Abstract][Full Text] [Related]
11. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas. Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490 [TBL] [Abstract][Full Text] [Related]
13. 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II. Hamada K; Tomita Y; Qiu Y; Zhang B; Ueda T; Myoui A; Higuchi I; Yoshikawa H; Aozasa K; Hatazawa J Ann Nucl Med; 2008 Oct; 22(8):699-705. PubMed ID: 18982473 [TBL] [Abstract][Full Text] [Related]
14. Is (18)F-fluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology? Deandreis D; Al Ghuzlan A; Auperin A; Vielh P; Caillou B; Chami L; Lumbroso J; Travagli JP; Hartl D; Baudin E; Schlumberger M; Leboulleux S Thyroid; 2012 Feb; 22(2):165-72. PubMed ID: 22257371 [TBL] [Abstract][Full Text] [Related]
15. Correlation between biological marker expression and F-fluorodeoxyglucose uptake in cervical cancer measured by positron emission tomography. Park SI; Suh DS; Kim SJ; Choi KU; Yoon MS Onkologie; 2013; 36(4):169-74. PubMed ID: 23548964 [TBL] [Abstract][Full Text] [Related]
16. Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18F-fluorodeoxyglucose positron emission tomography: interim analysis. Traugott AL; Dehdashti F; Trinkaus K; Cohen M; Fialkowski E; Quayle F; Hussain H; Davila R; Ylagan L; Moley JF World J Surg; 2010 Jun; 34(6):1247-53. PubMed ID: 20140435 [TBL] [Abstract][Full Text] [Related]
18. Ultrasound stratification of the FDG-avid thyroid nodule. Beech P; Lavender I; Jong I; Soo G; Ramdave S; Chong A; Nandurkar D Clin Radiol; 2016 Feb; 71(2):164-9. PubMed ID: 26683088 [TBL] [Abstract][Full Text] [Related]
19. Correlation between tumor glucose metabolism and multiparametric functional MRI (IVIM and R2*) metrics in cervical carcinoma: Evidence from integrated Li-Ou Z; Hong-Zan S; Xiao-Xi B; Zhong-Wei C; Zai-Ming L; Jun X; Qi-Yong G J Magn Reson Imaging; 2019 Jun; 49(6):1704-1712. PubMed ID: 30390401 [TBL] [Abstract][Full Text] [Related]
20. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma. Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]